European Society for Medical Oncology (ESMO) 21st World Congress on Gastrointestinal Cancer (WCGC)

TAS-118 + oxaliplatin outdoes S-1 + cisplatin in improving survival in advanced gastric cancer

Roshini Claire Anthony, 20190715140202

The combination of TAS-118 and oxaliplatin led to significantly greater survival compared with the S-1 and cisplatin combination in patients with metastatic or recurrent HER2-negative gastric cancer, the phase III SOLAR* study showed.

Dose reduction has little impact on regorafenib tolerability, efficacy not compromised

Roshini Claire Anthony, 20190712140203

Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.

Ramucirumab ups survival in advanced HCC regardless of prior TACE

Pearl Toh, 20190711190000

The survival benefit with ramucirumab was consistent in patients with advanced hepatocellular carcinoma (HCC) and high alpha-fetoprotein (AFP) levels regardless of whether they were previously treated with transarterial chemoembolization (TACE), a post hoc analysis of pooled data from the REACH/REACH-2 studies shows.

TRIBE studies underline survival benefit of FOLFOXIRI-bevacizumab in mCRC

Audrey Abella, 20190711100000

Augmenting the triple chemotherapeutic regimen FOLFOXIRI* with bevacizumab demonstrated favourable efficacy regardless of age and gender in patients with unresectable metastatic colorectal cancer (mCRC), according to data presented at the ESMO World Congress on Gastrointestinal Cancer (ESMO GI) 2019.

Add-on bevacizumab improves efficacy of trifluridine/tipiracil in mCRC

Elaine Soliven, 20190711000000

Adding bevacizumab to trifluridine/tipiracil (FTD/TPI) significantly improves progression-free survival (PFS) and overall survival (OS) compared with FTD/TPI in patients with chemorefractory metastatic colorectal cancer (mCRC), according to a study presented at ESMO GI 2019.

Triplet-targeted therapy a BEACON of hope for patients with BRAF-V600E mCRC

Pearl Toh, 20190709190000

A triple-drug combination therapy comprising encorafenib, binimetinib, and cetuximab significantly improved survival compared with the current standard of care chemotherapy in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had failed one or two prior treatments, according to the BEACON CRC study presented at the recent ESMO World Congress on Gastrointestinal Cancer (ESMO GI).